Skip to content
Screener

Cullinan Therapeutics, Inc. CGEM Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Eli Lilly logo
Eli LillyLLY
$7.48B+20.2%
Amgen logo
AmgenAMGN
$12.98B+17.7%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$2.2M-26.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Vor Biopharma logo
Vor BiopharmaVOR
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM

Other financials

Income statement

See full
Revenue-
Operating income-$57.3M+24.5%
Net income-$53.7M+23.3%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$78.6M+8.0%
Total debt$2.1M+36.3%
Total equity$408.7M-30.8%
Total assets$363.8M-30.1%

Cash flow

See full
Operating cash flow-$38.2M+33.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.14B+173%
Enterprise value$1.06B+206%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio8.4×-1.4×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336717
Line itemJune 30, 2026December 31, 2025
Total current assets341,974386,756
Property and equipment, net263421
Operating lease right-of-use assets2,2332,630
Other assets297297
Long-term investments19,02058,270
Total assets$363,787$448,374
Liabilities and Stockholders' Equity
Current liabilities:

Item 1. Financial Statements.

FAQ

What is Cullinan Therapeutics, Inc.'s deferred tax assets and other non-current assets?
Cullinan Therapeutics, Inc. (CGEM) reported deferred tax assets and other non-current assets of $297K in Q2 2026.
How has Cullinan Therapeutics, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
Cullinan Therapeutics, Inc.'s deferred tax assets and other non-current assets decreased by 19.1% year-over-year, from $367K to $297K.
What is the long-term trend for Cullinan Therapeutics, Inc.'s deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s deferred tax assets and other non-current assets has grown at a -33.6% compound annual growth rate (CAGR), from $2.3M to $297K.
What does deferred tax assets and other non-current assets mean?
Combined balance of non-current deferred tax assets and other miscellaneous non-current assets.

Ask your AI about Cullinan Therapeutics, Inc.'s deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude